BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25714017)

  • 21. Gene and cell therapy for pancreatic cancer.
    Singh HM; Ungerechts G; Tsimberidou AM
    Expert Opin Biol Ther; 2015 Apr; 15(4):505-16. PubMed ID: 25582170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
    Mosquera C; Maglic D; Zervos EE
    Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for pancreatic cancer in familial high-risk individuals: A systematic review.
    Lu C; Xu CF; Wan XY; Zhu HT; Yu CH; Li YM
    World J Gastroenterol; 2015 Jul; 21(28):8678-86. PubMed ID: 26229410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Personalized therapy for pancreatic cancer: Do we need better targets, arrows, or both?
    O'Hayer KM; Brody JR
    Discov Med; 2016 Feb; 21(114):117-23. PubMed ID: 27011047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measurement of copy number of ACTN4 to optimize the therapeutic strategy for locally advanced pancreatic cancer.
    Shoji H; Miura N; Ueno H; Honda K
    Pancreatology; 2018 Sep; 18(6):624-629. PubMed ID: 29921500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A Novel Treatment Strategy for Pancreatic Cancer Based on Gene Profiles].
    Hayashi H; Nishihara H
    Gan To Kagaku Ryoho; 2016 Nov; 43(11):1326-1331. PubMed ID: 27899773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pancreatic cancer genome revisited.
    Hayashi A; Hong J; Iacobuzio-Donahue CA
    Nat Rev Gastroenterol Hepatol; 2021 Jul; 18(7):469-481. PubMed ID: 34089011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pancreatic cancer: the role of molecular markers in diagnosis and management.
    Lowery MA; O'Reilly EM
    Clin Adv Hematol Oncol; 2011 Dec; 9(12):900-8. PubMed ID: 22252658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular pathogenesis of pancreatic cancer.
    Maitra A; Kern SE; Hruban RH
    Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):211-26. PubMed ID: 16549325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications.
    Rodriguez JA; Li M; Yao Q; Chen C; Fisher WE
    World J Surg; 2005 Mar; 29(3):297-305. PubMed ID: 15696394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier.
    Bhasin MK; Ndebele K; Bucur O; Yee EU; Otu HH; Plati J; Bullock A; Gu X; Castan E; Zhang P; Najarian R; Muraru MS; Miksad R; Khosravi-Far R; Libermann TA
    Oncotarget; 2016 Apr; 7(17):23263-81. PubMed ID: 26993610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review.
    Dhayat S; Mardin WA; Mees ST; Haier J
    Int J Cancer; 2011 Sep; 129(5):1031-41. PubMed ID: 21413017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
    Pishvaian MJ; Brody JR
    Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene therapy developments for pancreatic cancer.
    Bhattacharyya M; Lemoine NR
    Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):285-98. PubMed ID: 16549328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and future biomarkers for pancreatic adenocarcinoma.
    Loosen SH; Neumann UP; Trautwein C; Roderburg C; Luedde T
    Tumour Biol; 2017 Jun; 39(6):1010428317692231. PubMed ID: 28618958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarkers for personalized medicine in GI cancers.
    Zhang SY; Zhang SQ; Nagaraju GP; El-Rayes BF
    Mol Aspects Med; 2015 Nov; 45():14-27. PubMed ID: 26054566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular genetics of pancreatic intraepithelial neoplasia.
    Feldmann G; Beaty R; Hruban RH; Maitra A
    J Hepatobiliary Pancreat Surg; 2007; 14(3):224-32. PubMed ID: 17520196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications.
    Talar-Wojnarowska R; Malecka-Panas E
    Med Sci Monit; 2006 Sep; 12(9):RA186-93. PubMed ID: 16940943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.